Retrospective analysis of the clinical efficacy of a dendritic cell-based cancer vaccine in patients with advanced or recurrent breast cancer
Conclusion DC vaccine-based immunotherapy demonstrates promising OS times and tolerable toxicities in the setting of breast carcinoma. A full risk/benefit analysis of DC-based vaccines in patients with metastatic breast carcinoma will be determined in a future phase II trial.
Source: Personalized Medicine Universe - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Chemotherapy | Drugs & Pharmacology | HER2 | Study | Toxicology | Vaccines